Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 5, 2011, Pages 877-883

  Lauterlein, Jens Jacob L ^a   Petersen, Eva R B ^a   Olsen, Dorte Aa ^a   Østergaard, Birthe ^a   Brandslund, Ivan ^b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

autoantibodies; breast cancer; ErbB2; gene amplification; HER2 serum human epidermal growth factor receptor 2

Indexed keywords

AUTOANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOCAP; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TISSUE SECTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; BLOOD CHEMICAL ANALYSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GENE AMPLIFICATION; HUMANS; LIMIT OF DETECTION; MIDDLE AGED; RECEPTOR, ERBB-2; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS;

EID: 79954459329     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.135     Document Type: Article

References (19)

1. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997;15:3363-7. (Pubitemid 27485856)
2. Disis ML, Cheever MA. Oncogenic proteins as tumor antigens. Curr Opin Immunol 1996;8:637-42. (Pubitemid 26385391)
3. Ward RL, Hawkins NJ, Coomber D, Disis ML. Antibody immunity to the HER-2/neu oncogenic protein in patients with colo-rectal cancer. Hum Immunol 1999;60:510-5. (Pubitemid 29296307)
4. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000;60:1777-88. (Pubitemid 30207629)
5. Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007;18:868-73. (Pubitemid 47054083)
6. Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 2008;7:1388-94.
7. Ramieri MT, Murari R, Botti C, Pica E, Zotti G, Alo PL. Detection of HER2 Amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma. Anticancer Res 2010;30:1287-92.
8. Rees SB, McLachlan SM, Furmaniak J. Autoantibodies to the thyrotropin receptor. Endocr Rev 1988;9:106-21.
9. Akamizu T, Matsuda F, Okuda J, Li H, Kanda H, Watanabe T, et al. Molecular analysis of stimulatory anti-thyrotropin receptor antibodies (TSAbs) involved in Graves' disease. Isolation and reconstruction of antibody genes, and production of mono-clonal TSAbs. J Immunol 1996;157:3148-52. (Pubitemid 126450076)
10. Akamizu T, Moriyama K, Miura M, Saijo M, Matsuda F, Nakao K. Characterization of recombinant monoclonal antithyrotropin receptor antibodies (TSHRAbs) derived from lymphocytes of patients with Graves' disease: epitope and binding study of two stimulatory TSHRAbs. Endocrinology 1999;140:1594-601. (Pubitemid 29149227)
11. Bech K. Immunological aspects of Graves' disease and impor-tance of thyroid stimulating immunoglobulins. Acta Endocrinol Suppl (Copenh) 1983;254:3-38.
12. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51. (Pubitemid 47026733)
13. Shalaby MR, Shepard HM, Presta L, Rodrigues ML, Beverley PC, Feldmann M, et al. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J Exp Med 1992; 175:217-25.
14. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 1992;89: 4285-9.
15. Leveque D, Gigou L, Bergerat JP. Clinical pharmacology of trastuzumab. Curr Clin Pharmacol 2008;3:51-5. (Pubitemid 351210965)
16. Olsen DA, Ostergaard B, Bokmand S, Wamberg PA, Jakobsen EH, Brandslund I. HER-2 protein concentrations in breast can-cer cells increase before immunohistochemical and fluores-cence in situ hybridization analysis turn positive. Clin Chem Lab Med 2007;45:177-82. (Pubitemid 46294685)
17. Mutluhan H, Akbas E, Erdogan NE, Soylemez F, Senli MS, Polat A, et al. The influence of HER2 genotypes as molecular markers on breast cancer outcome. DNA Cell Biol 2008;27: 575-9.
18. Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, et al. Population-based, case-control study of HER2 genetic poly-morphism and breast cancer risk. J Natl Cancer Inst 2000;92: 412-7. (Pubitemid 30154823)
19. Ameyaw MM, Tayeb M, Thornton N, Folayan G, Tariq M, Mobarek A, et al. Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. J Hum Genet 2002;47:172-5. (Pubitemid 34496176)